Purpose To update the ASCO guideline for antiemetics in oncology. Methods ASCO
convened an Expert Panel and conducted a systematic review of the medical literature for …

Despite the considerable progress achieved in the last 30 years, vomiting and, especially,
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …

Background About 70% to 80% of adults with cancer experience chemotherapy‐induced
nausea and vomiting (CINV). CINV remains one of the most distressing symptoms …

Patients with cancer should appropriately receive antiemetic therapies against
chemotherapy-induced nausea and vomiting (CINV). Antiemetic guidelines play an …

Nausea and vomiting are still considered to be two of the most troublesome adverse events
(AEs) for patients treated with antineoplastic therapy. To optimise the utility of available …

Background: The NEDD8 conjugation pathway modulates the ubiquitination and activity of a
wide range of intracellular proteins, and its blockade by pevonedistat is emerging as a …

Objectives MiR‐34 is a tumour suppressor in breast cancer. Neurokinin‐1 receptor (NK1R),
which is the predicted target of the miR‐34 family, is overexpressed in many cancers. This …

Purpose An update of the recommendations for the prophylaxis of acute and delayed
emesis induced by moderately emetogenic chemotherapy published after the last …

Importance The prevention of chemotherapy-induced nausea and vomiting has an important
role in the overall management of cancer treatment. Objective To evaluate whether adding …

To examine pharmacologic and clinical characteristics of neurokinin 1 (NK1)-receptor
antagonists (RAs) for preventing chemotherapy-induced nausea and vomiting (CINV) …